Hope for sanfilippo kids: Brain-Infused drug enters final testing
NCT ID NCT07579910
First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 3 times
Summary
This phase 3 trial tests a drug called tralesinidase alfa in 14 children aged 1-5 with Sanfilippo syndrome type B, a rare genetic disease that causes severe brain damage. The drug is given directly into the brain fluid to replace a missing enzyme. The goal is to see if it can slow cognitive decline compared to standard care over 5 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tralesinidase alfa
- What this could lead to
- If it works, this could slow cognitive decline in children with Sanfilippo syndrome type B, offering a treatment option for this rare, devastating disease.
- What could go wrong
- This is a small, early-stage trial with only 14 participants. The drug is given directly into the brain, which carries risks like infection or side effects. Success is not guaranteed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MPS IIIB are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••